Compendium of Cancer Genome Aberrations

HAEM5:Volunteer Assignments and Opportunities: Difference between revisions

[checked revision][checked revision]
← Older editNewer edit →
VisualWikitext
No edit summary
No edit summary
Line 1,598: Line 1,598:
|Lei Zhang, PhD
|Lei Zhang, PhD
|10/10/2025
|10/10/2025
|
|12/22/2025
|Pending
|Pending
|
|
Line 2,485: Line 2,485:
|
|
|
|
|Pending
|
|
|
|SK
|SK
Line 2,557: Line 2,557:
|
|
|-
|-
|[[HAEM5:Aggressive NK-cell leukaemia|Aggressive NK-cell leukaemia]]||Disease||Rabail Aslam, MD (fellow);
|[[HAEM5:Aggressive NK-cell leukaemia|Aggressive NK-cell leukaemia]]||Disease||Shashirekha Shetty, PhD
Shashirekha Shetty, PhD
|10/15/2025||1/19/2026
|10/15/2025||1/19/2026
|Pending
|Pending
Line 2,586: Line 2,585:
|[[HAEM5:Primary cutaneous CD4-positive small or medium T-cell lymphoproliferative disorder|Primary cutaneous CD4-positive small or medium T-cell lymphoproliferative disorder]]||Disease||Amanda Xu, MD/MSc; Teodora Popa (resident)
|[[HAEM5:Primary cutaneous CD4-positive small or medium T-cell lymphoproliferative disorder|Primary cutaneous CD4-positive small or medium T-cell lymphoproliferative disorder]]||Disease||Amanda Xu, MD/MSc; Teodora Popa (resident)
|3/19/2024
|3/19/2024
| ||Pending
| ||
| ||SK|| ||
| ||SK|| ||
|NEW (No Prior)
|NEW (No Prior)
Line 2,618: Line 2,617:
Shashirekha Shetty, PhD
Shashirekha Shetty, PhD
|7/1/2024
|7/1/2024
|8/31/224
|
|Pending
|
| ||SK|| ||
| ||SK|| ||
|NEW (No Prior)
|NEW (No Prior)
Line 2,629: Line 2,628:
|[[HAEM5:Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Primary cutaneous anaplastic large cell lymphoma|Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Primary cutaneous anaplastic large cell lymphoma]]||Disease||Rabail Aslam, MD (fellow);
|[[HAEM5:Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Primary cutaneous anaplastic large cell lymphoma|Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Primary cutaneous anaplastic large cell lymphoma]]||Disease||Rabail Aslam, MD (fellow);
Shashirekha Shetty, PhD
Shashirekha Shetty, PhD
|7/1/2024||8/31/2024
|7/1/2024||
|Pending
|
| ||SK|| ||
| ||SK|| ||
|Primary Cutaneous Anaplastic Large Cell Lymphoma
|Primary Cutaneous Anaplastic Large Cell Lymphoma
Line 2,640: Line 2,639:
|[[HAEM5:Subcutaneous panniculitis-like T-cell lymphoma|Subcutaneous panniculitis-like T-cell lymphoma]]||Disease||Raniah Alamri (Hemepath trainee)
|[[HAEM5:Subcutaneous panniculitis-like T-cell lymphoma|Subcutaneous panniculitis-like T-cell lymphoma]]||Disease||Raniah Alamri (Hemepath trainee)
|3/19/2024
|3/19/2024
| ||Pending
| ||
| ||SK|| ||
| ||SK|| ||
|NEW (No Prior)
|NEW (No Prior)
Line 2,651: Line 2,650:
Sumire Kitahara, MD
Sumire Kitahara, MD
|6/30/2024
|6/30/2024
| ||Pending
|11/9/2025
|Pending
| ||SK|| ||
| ||SK|| ||
|NEW (No Prior)
|NEW (No Prior)
Line 2,751: Line 2,751:


Sumire Kitahara, MD
Sumire Kitahara, MD
|6/6/24|| ||Pending
|6/6/24|| ||
| ||SK|| ||
| ||SK|| ||
|Anaplastic Large Cell Lymphoma, ALK-Positive
|Anaplastic Large Cell Lymphoma, ALK-Positive
Line 2,765: Line 2,765:
|[[HAEM5:ALK-negative anaplastic large cell lymphoma|ALK-negative anaplastic large cell lymphoma]]||Disease||Miguel Gonzalez Mancera, MD (trainee);
|[[HAEM5:ALK-negative anaplastic large cell lymphoma|ALK-negative anaplastic large cell lymphoma]]||Disease||Miguel Gonzalez Mancera, MD (trainee);
Sumire Kitahara, MD
Sumire Kitahara, MD
|6/6/24|| ||Pending
|6/6/24|| ||
| ||SK|| ||
| ||SK|| ||
|Anaplastic Large Cell Lymphoma, ALK-Negative
|Anaplastic Large Cell Lymphoma, ALK-Negative
Line 2,800: Line 2,800:
|-
|-
|[[HAEM5:Nodal TFH cell lymphoma, angioimmunoblastic-type|Nodal TFH cell lymphoma, angioimmunoblastic-type]]||Disease||Rachel Burnside, PhD||7/28/2023
|[[HAEM5:Nodal TFH cell lymphoma, angioimmunoblastic-type|Nodal TFH cell lymphoma, angioimmunoblastic-type]]||Disease||Rachel Burnside, PhD||7/28/2023
| ||Pending|| ||SK|| ||prior authors not available
| || || ||SK|| ||prior authors not available
|Angioimmunoblastic T-cell Lymphoma
|Angioimmunoblastic T-cell Lymphoma
|Sara Akhavanfard, M.D., Ph.D. and Ruthann Pfau, Ph.D., FACMG
|Sara Akhavanfard, M.D., Ph.D. and Ruthann Pfau, Ph.D., FACMG
Line 2,808: Line 2,808:
|-
|-
|[[HAEM5:Nodal TFH cell lymphoma, follicular-type|Nodal TFH cell lymphoma, follicular-type]]||Disease||Rachel Burnside, PhD||7/28/2023
|[[HAEM5:Nodal TFH cell lymphoma, follicular-type|Nodal TFH cell lymphoma, follicular-type]]||Disease||Rachel Burnside, PhD||7/28/2023
| ||Pending|| ||SK|| ||
| || || ||SK|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
Line 2,824: Line 2,824:
|-
|-
|[[HAEM5:Peripheral T-cell lymphoma, NOS|Peripheral T-cell lymphoma, NOS]]||Disease||Bo Hong, MD
|[[HAEM5:Peripheral T-cell lymphoma, NOS|Peripheral T-cell lymphoma, NOS]]||Disease||Bo Hong, MD
|6/25/2023
|10/14/2025
| || || ||SK|| ||
|12/3/2025
|Pending
| ||SK|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
Line 2,868: Line 2,870:
|[[HAEM5:Systemic chronic active EBV disease|Systemic chronic active EBV disease]]||Disease||Karin Miller, MD
|[[HAEM5:Systemic chronic active EBV disease|Systemic chronic active EBV disease]]||Disease||Karin Miller, MD
|3/25/2024
|3/25/2024
| || || ||SK|| ||
| ||Pending
| ||SK|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
Line 2,877: Line 2,880:
|[[HAEM5:Systemic EBV-positive T-cell lymphoma of childhood|Systemic EBV-positive T-cell lymphoma of childhood]]||Disease||Karin Miller, MD
|[[HAEM5:Systemic EBV-positive T-cell lymphoma of childhood|Systemic EBV-positive T-cell lymphoma of childhood]]||Disease||Karin Miller, MD
|3/25/2024
|3/25/2024
| || || ||SK|| ||prior authors not available
| ||Pending
| ||SK|| ||prior authors not available
|Systemic EBV-Positive T-cell Lymphoma of Childhood
|Systemic EBV-Positive T-cell Lymphoma of Childhood
|Lisa A. Lansdon, PhD and Linda D. Cooley, MD, MBA
|Lisa A. Lansdon, PhD and Linda D. Cooley, MD, MBA
Retrieved from "https://test.ccga.io/index.php/HAEM5:Volunteer_Assignments_and_Opportunities"